Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02086604 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: Brentuximab vedotin
DRUG: Lenalidomide

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]